View all research projects
Research project

Production of Technology Assessment Reviews (TARs) for the National Institute of Health Research (NIHR) 2022-2027

Staff

Lead researchers

Professor Joanne Lord

Director of SHTAC
Research interests
  • Joanne has research interests in health economic evaluation and decision modelling.
  • She has worked on a wide range of applied cost-effectiveness studies, including:
  • a review of newborn screening for inborn errors of metabolism;trials of diagnosis, patient ed…
Connect with Joanne

Email: J.Lord@soton.ac.uk

Other researchers

Dr Jonathan Shepherd PhD

Principal Research Fellow
Connect with Jonathan

Email: Jonny.Shepherd@soton.ac.uk

Collaborating research institutes, centres and groups

Research outputs

Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]
Emma Maund, Marcia Takahashi, Joanne Lord & Jonathan Shepherd, 2025
Type: report
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation
Karen Pickett, Marcia Takahashi, Neelam Kalita & Jonathan Shepherd, 2025
Type: report
Bevacizumab gamma for treating wet age-related macular degeneration
Jonathan Shepherd, Fay Chinnery, Emma Maund, David Alexander Scott & Joanne Lord, 2024
Type: report
Transperineal biopsy devices in people with suspected prostate cancer - a systematic review and economic evaluation
Ines Souto-Ribeiro, Lois Woods, Emma Maund, David Alexander Scott, Joanne Lord, Joanna Picot & Jonathan Shepherd, 2024, Health Technology Assessment, 28(60)
DOI: 10.3310/ZKTW8214
Type: article
Molnupiravir for COVID-19 (ID6340).
Ines Ribeiro, Lois Woods, Neelam Kalita, David Alexander Scott & Geoff Frampton, 2024
Type: report
An economic evaluation of local anaesthetic transperineal biopsy in people with suspected prostate cancer
Ines Ribeiro, Lois Woods, Emma Maund, David Alexander Scott, Joanne Lord, Jo Picot & Jonathan Shepherd, 2024
Type: conference
Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]
Emma Maund, Fay Chinnery, Keith Cooper & Jonathan Shepherd, 2024
Type: report